Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Sarcoma in 2016

Evolving biological understanding and treatment of sarcomas

Nature Reviews Clinical Oncology volume 14, pages 78–80 (2017)Cite this article

Subjects

In 2016, novel findings on the role of predisposing gene variants in sarcoma oncogenesis were published, as well as studies addressing novel molecular classifications and results from randomized controlled trials highlighting successful new treatments. Herein, we discuss these meaningful advances.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25 (Suppl. 3), iii102–iii112 (2014).

  2. Ballinger, M. I. et al. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol. 17, 1261–1271 (2016).

    Article  Google Scholar 

  3. Plon, S. E. et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum. Mutat. 29, 1282–1291 (2008).

    Article  CAS  Google Scholar 

  4. Judson, I. et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 15, 415–423 (2014).

    Article  CAS  Google Scholar 

  5. Seddon, B. M. et al. GeDDiS: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas (EudraCT 2009- 014907-29) [abstract]. J. Clin. Oncol. 33, a10500 (2015).

    Article  Google Scholar 

  6. Ryan, C. W. et al. PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma. J. Clin. Oncol. 34, 3898–3905 (2016).

    Article  CAS  Google Scholar 

  7. Tap, W. et al. Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) versus D alone in patients (pts) with metastatic soft tissue sarcomas. Ann. Oncol. 27, 483–492 (2016).

    Article  Google Scholar 

  8. Tap, W. D. et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 388, 488–497 (2016).

    Article  CAS  Google Scholar 

  9. Demetri, G. D. et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J. Clin. Oncol. 34, 786–793 (2015).

    Article  Google Scholar 

  10. Schoffski, P. et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387, 1629–1637 (2016).

    Article  CAS  Google Scholar 

  11. Penel, N. et al. Regorafenib (RE) in liposarcomas (LIPO), leiomyosarcomas (LMS), synovial sarcomas (SYN), and other types of soft-tissue sarcomas (OTS): results of an international, double-blind, randomized, placebo (PL) controlled phase II trial [abstract]. J. Clin. Oncol. 34, a11003 (2016).

    Article  Google Scholar 

  12. Boikos, S. A. et al. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol. 2, 922–928 (2016).

    Article  Google Scholar 

Download references

Acknowledgements

J-Y.B. receives support from Association DAM's, Ensemble contre Le GIST, Eurosarc (FP7-278742), Fondation ARC, Infosarcome, InterSARC (INCA), LabEx DEvweCAN (ANR-10-LABX-0061), Ligue de L'Ain contre le Cancer, LYric (DGOS-INCa-4664), NetSARC and RREPS (both INCA). I. R-C. receives support from Association DAM's, Fondation ARC, Ligue de L'Ain contre le Cancer, LYric (DGOS-INCa-4664), NetSARC (INCA) and RREPS (INCA).

Author information

Authors and Affiliations

  1. Jean-Yves Blay and Isabelle Ray-Coquard are at the Department of Medical Oncology, Centre Leon Berard, 28, rue Laennec 69008, Lyon, France.,

    Jean-Yves Blay & Isabelle Ray-Coquard

Authors
  1. Jean-Yves Blay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Isabelle Ray-Coquard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jean-Yves Blay.

Ethics declarations

Competing interests

J-Y.B. receives research support and honoraria from Eisai, Eli Lilly, GSK, Ignyta, Novartis, Pharmamar and Roche. I.R-C. receives research support and honoraria from Eli Lilly, Pharmamar and Roche.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Blay, JY., Ray-Coquard, I. Evolving biological understanding and treatment of sarcomas. Nat Rev Clin Oncol 14, 78–80 (2017). https://doi.org/10.1038/nrclinonc.2016.200

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2016.200

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer